HEPATOCELLULAR CARCINOMA (HCC)

This study is observing how well a radiation treatment called 90Y works for people with early-stage liver cancer. Researchers are tracking 200 patients at four Korean hospitals to see how long they live, how their tumors respond, and what side effects occur. The goal is to gather…

This study is testing a new, more stable mixture of an oil and a chemotherapy drug. It is used in a two-step procedure for patients with early-stage liver cancer who cannot or choose not to have surgery. First, the mixture is injected to block the tumor's blood supply and deliver…

This study is testing a new combination of two drugs, cobolimab and dostarlimab, for children and young adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest and most effective dose and to see how well the body tolera…

This early-stage study is testing the safety of a three-part treatment for liver cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (JS014 and Toripalimab) with a standard procedure that blocks the tumor's blood supply (TACE). The goal is to …

This study is testing whether a radiation treatment for small liver cancer tumors can be safely done in one day instead of two. Researchers aim to simplify the process for 30 patients by removing a safety scan they believe is unnecessary for small tumors. The goal is to reduce pa…

This study is testing a three-part treatment for liver cancer that cannot be surgically removed. First, doctors deliver tiny radioactive beads directly to the tumor. Then, patients receive two immunotherapy drugs (durvalumab and bevacizumab) to help the immune system fight the ca…

This trial is testing a combination of two approved drugs (toripalimab and bevacizumab) with three different procedures that deliver treatment directly into the liver's arteries. The goal is to see which combined approach works best to shrink tumors and control advanced liver can…

This study is testing whether a combination of two drugs, camrelizumab and rivoceranib, can help prevent liver cancer from returning in patients who are at high risk of recurrence after their initial tumor has been surgically removed or destroyed. The trial will compare the drug …

This was a small, early study that planned to test a new combination treatment for liver cancer that could be removed with surgery. The goal was to see if giving a short course of targeted radiation along with two immunotherapy drugs before the operation was safe and showed signs…

This study is testing whether combining two types of medical scans (PET and MRI) with artificial intelligence (AI) can more accurately determine how aggressive a solid tumor is. It involves about 135 adults with prostate cancer or other solid tumors like liver or brain cancer. Th…

This study is testing if a shorter, more affordable MRI scan is better than the standard ultrasound for finding early liver cancer in people with cirrhosis. Researchers will enroll 820 adults with cirrhosis who are already in a screening program. They will compare how well the fa…

This study is testing whether a digital tool can help people with liver cancer feel better during immunotherapy. Researchers want to see if patients who report their symptoms weekly through a smartphone app get better care advice and have a better quality of life than those who d…